Dated: July 19, 2013. Leslie Kux, Assistant Commissioner for Policy. [FR Doc. 2013–17769 Filed 7–23–13; 8:45 am] BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Sickle Cell Disease Treatment Demonstration Program

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS). **ACTION:** Request for Class Deviation for

Non-Competitive Extension: Sickle Cell Disease Treatment Demonstration Program (U1E) Awards to Three Currently Funded Grantees.

SUMMARY: HRSA currently has nine programs that are funded through competitive grant awards under the Sickle Cell Disease Treatment Demonstration Program. Three of these awards will end on August 31, 2013, prior to the end of the other six awards. HRSA intends to implement a noncompetitive extension of the project period for the three grants that will end in 2013. This will allow improved data gathering from each of the grantees in the program, which will be used in a report for Congress that is mandated by the legislation authorizing the grant. In addition, the program will benefit from cost savings realized from having the program completed in a consolidated funding cycle.

SUPPLEMENTARY INFORMATION:

Intended Recipients of the Award: The three incumbent grantees of record (listed below).

Amount of the Non-Competitive Awards: Up to \$390,000 per grantee.

CFDA Number: 93.365

Period of Supplemental Funding: 9/1/2013–8/30/2014.

Authority: Section 712(c) of the American Jobs Creation Act of 2004, Pub. L. 108–357.

Justification: The Sickle Cell Disease Treatment Demonstration Program provides grants to evaluate the use of strategies in improving sickle cell care.

The extension will allow the Maternal and Child Health Bureau to fully assess the impact of the program by allowing data to be gathered on the health outcomes and impact of the Sickle Cell **Disease Treatment Demonstration** Program from all grantees on the same timeline and in a standard format. Currently, three grantees are scheduled to end prior to the end of the other grantees, leaving a period in which data would not be gathered from these sites. Data gathered from each of the grantees in the program will be used in a report for Congress that is mandated by the legislation authorizing the grant. In addition, the program will benefit from cost savings realized from having the program completed in a consolidated funding cycle.

FOR FURTHER INFORMATION CONTACT:

Edward Donnell Ivy, M.D., M.P.H, Genetic Services Branch, Division of Services for Children with Special Health Needs, Maternal and Child Health Bureau, Health Resources and Services Administration, 5600 Fishers Lane, Room 18A–19, Rockville, MD 20857; 301.443.9775; *eivy@hrsa.gov*.

MATERNAL AND CHILD HEALTH BUREAU SELECTED PROGRAMS EXTENSIONS WITH FUNDING

Grantee/organization name	Grant No.	State	Project start date	Project end date	Revised project end date	FY 2012 Appropriation	FY 2013 Appropriation
Children's Hospital & Research Center.	U1EMC16492	CA	9/1/2009	8/31/2013	8/30/2014	\$390,000	\$390,000
University of Colorado at Den- ver.	U1EMC16490	со	9/1/2009	8/31/2013	8/30/2014	390,000	390,000
Newark Beth Israel Medical Center.	U1EMC16491	NJ	9/1/2009	8/31/2013	8/30/2014	390,000	390,000

Dated: July 17, 2013. **Mary K. Wakefield,** *Administrator.* [FR Doc. 2013–17720 Filed 7–23–13; 8:45 am] **BILLING CODE 4165–15–P**

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of the Council of Councils.

The meeting will be held via teleconference and is open to the public as indicated below. Individuals who need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

A portion of the meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4), and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Council of Councils. Open: August 15, 2013, 1:00 p.m. to 1:40 p.m.

Agenda: Establishment of Chimpanzee Research Use Panel and Discussion. Vote on Establishment of the Panel. NIH Director's Early Independence Awards. *Place*: National Institutes of Health, Building 1, Room 260, 1 Center Drive, Bethesda, MD 20892.

Dial in number: 1-888-790-1964.

Participant Passcode: 9121608.

Closed: August 15, 2013, 1:45 p.m. to 2:15 p.m.

Agenda: Review of Grant Applications. Contact Person: Robin Kawazoe, Executive Secretary, Division of Program Coordination, Planning, and Strategic Initiatives, Office of the Director, NIH, Building 1, Room 260, Bethesda, MD 20892,

kawazoer@mail.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Council of Council's home page at http:// dpcpsi.nih.gov/council/where an agenda and proposals to be discussed will be posted before the meeting date.